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Objective: To compare the efficacy of theophylline plus salmeterol/fluticasone propionate
combination product (SFC) with SFC plus placebo in asthmatic patients.
Methods: In this randomized, stratified, parallel-group study, 325 patients were randomized to
receive either 200 mg theophylline plus 50/250 mg SFC or placebo tablet plus 50/250 mg SFC
twice daily for 24 weeks. Outcome variables included the level of asthma control (assessed
by the Asthma Control Test) and the number of patients experiencing 1 exacerbations during
the 24-week treatment period. Testing of lung function as well as measurement of the levels of
inflammatory markers in induced sputum was performed.
Results: There were significantly fewer patients with 1 asthma exacerbation in the theoph-
ylline plus SFC group (29.6%) when compared with the SFC plus placebo group (46.9%)
(p Z 0.004). Theophylline plus SFC improved the FEF25e75% value, which indicates enhanced
small airway function, to a greater extent than SFC plus placebo (66.9  18.8% and
57.4  17.6%, respectively; p < 0.001). A significant decrease in eosinophil count and concen-
tration of eosinophil cationic protein in induced sputum was also seen in the theophylline plus
SFC group when compared with the SFC plus placebo group (4.1  2.2% and 6.3  2.7%,
63.6  39.5 mg/L and 89.4  45.6 mg/L, respectively; all p < 0.01).
Conclusion: The combination of theophylline plus SFC may provide greater protection against
asthma exacerbations, and its administration is accompanied by significant improvements in
small airway function and airway inflammation.
ª 2012 Elsevier Ltd. All rights reserved.8804 1919x82137; fax: þ86 27 8804 2292.
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348 H. Nie et al.Introduction not take any anti-asthma medication before the trial. All
patients had one or more positive skin prick test reactionsAsthma is a chronic disease that is characterized by
inflammation, obstruction and hyperresponsiveness of the
airways. The aims of asthma management are to achieve
and maintain asthma control by treating inflammation and
relieving bronchoconstriction and symptoms.1 Current
guidelines for asthma management concur that inhaled
corticosteroids (ICS) are the mainstays of anti-inflammatory
treatment of asthma.1e3 Nevertheless, asthma is often
inadequately controlled, even with high doses of ICS, war-
ranting additional therapies. Accordingly, long-acting b2
agonists (LABAs) are commonly used in combination with
ICS therapy.1 While the addition of LABAs to ICS treatment
results in an improvement in symptom scores and reduces
exacerbation, recent studies have shown that insufficiently
controlled asthma remains a significant problem, even
when ICS and LABAs are titrated to the maximal dose.4,5
Therefore, alternative therapies that can be added to
either ICS or ICS plus LABAs therapy regimens are needed.
Theophylline, amethylxanthine, has beenwidely used for
the treatment of asthma, and is seen to have a role in asthma
management guidelines.6,7 However, its popularity has
declined because theophylline is a less effective broncho-
dilator agent than b2 agonists. Furthermore, theophylline
has a narrow therapeutic index, and the dose must be
carefully titrated with routine blood monitoring to maintain
blood levels within the therapeutic range of 10e20 mg/mL
and to avoid the occurrence of side effects, which include
nausea, vomiting, and cardiac arrhythmias. Despite these
concerns, theophylline is widely used in clinical practice in
China. Recent studies have shown that theophylline has anti-
inflammatory and immunomodulatory effects at lower
concentrations ranging from 5 to 10 mg/mL.8,9 Some studies
have shown that theophylline can be used in patients with
milder asthma or as an add-on therapy to low doses of
inhaled corticosteroids.8e11 No serious adverse effects have
been reported in these studies. As a result, we hypothesized
that a theophylline plus salmeterol/fluticasone propionate
combination would be more effective than salmeterol/flu-
ticasone propionate combination alone in patients with
asthma. The aim of this study was to compare the efficacy of
theophylline (200 mg twice daily) plus inhaled salmeterol/
fluticasone propionate combination (SFC, 50/250 mg twice
daily) with inhaled salmeterol/fluticasone propionate
combination (50/250 mg twice daily) plus placebo.
Methods
Patients
The study was conducted between October 2009 and March
2012 in the Department of Respiratory Medicine of Renmin
Hospital of Wuhan University (Wuhan, China), and was
approved by the Ethics Committee of Renmin Hospital of
Wuhan University. All patients gave written informed
consent. Four hundred and seven non-smoking adult asth-
matic patients aged between 18 and 68 who fulfilled the
diagnostic criteria of the Global Initiative for Asthma were
enrolled. All patients who were diagnosed as asthmatics didand did not experience a lower respiratory tract infection
at least 8 weeks prior to the trial. Patients who had expe-
rienced an exacerbation of asthma or who had taken
theophylline or any other treatment for asthma (except
inhaled salmeterol/fluticasone propionate combination or
salbutamol inhaler) within four weeks of the run-in period
were ineligible. Patients with a history of serious diseases
or other lung conditions, as well as current smokers, were
not admitted into the study. Pregnant or lactating females
were also excluded from study entry.Study protocol
This randomized, stratified, parallel-group study was con-
ducted in the Department of Respiratory Medicine of
Renmin Hospital of Wuhan University (Wuhan, China). A
screening visit was followed by a 4-week run-in period,
randomization at baseline, and a 24-week treatment
period. The patients kept diary cards throughout the study.
The patients returned for evaluation every four weeks
during the treatment period.
Screening visit
At screening, the patients underwent the following inves-
tigations: medical history and routine physical examina-
tion; laboratory work-up, including hematology and
biochemistry; pulmonary function testing, including forced
expiratory volume in 1 s (FEV1, expressed as a percentage
of the predicted normal value), forced vital capacity (FVC),
forced expiratory flow between 25% and 75% of FVC
(FEF25e75%, expressed as a percentage of the predicted
normal value), and peak expiratory flow (PEF). Spirometry
(Vmax229, United States Sensor-Medics, Yorba Linda) was
used to measure FEV1, FVC and FEF25e75%. PEF measure-
ments were made with a Mini-Wright Peak Flow Meter
(Shanghai Wanbo Scientific and Technological Ltd,
Shanghai, China). Patients performed three measurements
each morning and evening before taking their study medi-
cations, and recorded the best of the three measurements
each time.
Patients were then prescribed a salmeterol/fluticasone
propionate combination inhaler (SFC, 50/250 mg/puff) and
instructed to take 50/250 mg twice daily during the run-in
period. A salbutamol inhaler (Glaxo Wellcome, Chongqing,
China) was also dispensed, and patients were instructed to
use this as needed.
The patients were issued a diary card and asked to make
two entries per day describing their salbutamol usage and
the severity of their symptoms. Symptoms and salbutamol
usage recorded in the morning indicate events from the
previous night, and information recorded in the evening
refers to events that took place during the day. At the end
of 4-week run-in period, patients were asked to complete
the five-question Asthma Control Test (ACT), which consists
of five questions rated on a scale from 1 to 5 (Table 1).12
The results of individual questions were added up to
a total score, which ranged between 5 (completely
uncontrolled asthma) and 25 (completely controlled
Table 1 Individual questions of the Asthma Control Test
(ACT).
1 In the past 4 weeks, how much of the time did your
asthma keep you from getting as much done at work,
school or at home as usual?
2 During the past 4 weeks, how often have you had
shortness of breath?
3 During the past 4 weeks, how often did your asthma
symptoms (wheezing, coughing, shortness of breath,
chest tightness or pain) wake you up at night or earlier
than usual in the morning?
4 During the past 4 weeks, how often have you used your
rescue inhaler or nebulizer medication (such as
salbutamol)?
5 How would you rate your asthma control during the
past 4 weeks?
Score of 1 Z worst asthma control for each question; score of
5 Z best asthma control for each question.
Theophylline combination therapy on asthma 349asthma). To undergo randomization, patients had to have
a total ACT score of 10 at the end of 4-week run-in period.
Patients with a total ACT score of <10 were excluded due to
the possibility that the severity of their illness might
compel them to drop out of the study for safety reasons.
Patients who had a total score of 25 at the end of 4-week
run-in period were withdrawn.
Baseline and randomization
For the baseline measurement, pulmonary function was
assessed. The diurnal PEF variability from the last week of
the run-in period served as the baseline value. Before
treatment, sputum induction was performed to measure
the levels of inflammatory markers. Patients were then
randomized to either 50/250 mg of salmeterol/fluticasone
propionate combination plus 200 mg of theophylline or 50/
250 mg of salmeterol/fluticasone propionate combination
plus matched placebo. All doses were given twice daily.
Randomization was stratified to ensure that the severity of
symptoms was equal in the two groups. There were two
strata of severity, which were defined according to FEV1:
One group of patients had a FEV1 less than 60% of the
predicted normal value, and the other group had a FEV1
greater than 60%. Blood samples were taken to measure
baseline theophylline levels.
Study visits
During the treatment period, the patients returned to the
clinic after 4, 8, 12, 16, 20 and 24 weeks of treatment. Their
symptoms were recorded, and all patients were asked to
complete the five-question Asthma Control Test (ACT) to
assess asthma control. The incidence of exacerbations of
asthma was recorded during the 24-week treatment period.
Pulmonary functionwasmeasured at each visit. At the end of
the 24-week treatment period, sputum induction was per-
formed again to measure levels of inflammatory markers.
Assessments
The primary endpoints were asthma control and asthma
exacerbations. Asthma control was assessed by scoring thepatients’ responses to the ACT, which consists of five
questions rated on a scale from 1 to 5 (Table 1). The
results of individual questions were added up to yield
a total score, which ranged from 5 (completely uncon-
trolled asthma) to 25 (completely controlled asthma).12
Patients were placed into the following four categories
based on their results: (1) <16, uncontrolled; (2) 16 to
19, poorly controlled; (3) 20 to 24, well controlled;
and (4) 25, completely controlled. The incidence and
severity of asthma exacerbations were recorded. Exacer-
bations of asthma were classified as mild (a deterioration
in asthma symptoms requiring a clinically relevant
increase in salbutamol use, which is defined as more than
three additional inhalations per 24-h period with respect
to baseline for >2 consecutive days), moderate (requiring
oral corticosteroids and/or antibiotics) or severe
(requiring hospitalization).13 Severity of asthma exacer-
bations was judged by the investigator. Patients were
withdrawn from the study in the event of moderate or
severe exacerbations of asthma.
The secondary endpoints were changes of pulmonary
function and the levels of inflammatory markers in induced
sputum. Pulmonary function testing included measure-
ments of FEV1, FVC, FEF25e75% and peak expiratory flow
(PEF). Spirometry (Vmax229, United States Sensor-Medics,
Yorba Linda) was used to measured FEV1, FVC and
FEF25e75%. PEF measurements were made with a Mini-
Wright Peak Flow Meter (Shanghai Wanbo Scientific and
Technological Ltd, Shanghai, China). After being instructed
by the investigator, patients made three measurements
each morning and evening before taking their study medi-
cations, and recorded the best of the three measurements
each time. Diurnal variability in PEF was expressed as the
mean value during the final week of the run-in period or the
treatment period, and was calculated with the following
formula: (highest daily valuelowest daily value)/((highest
daily value þ lowest daily value)/2).
Sputum was induced and processed as previously
described.14 An eosinophil count was performed using
Wright’s stain. Five hundred non-squamous cells were
counted in Wright’s-stained slides and the results were
expressed as percentage of the non-squamous counts. The
concentration of eosinophil cationic protein (ECP) was
measured (mg/ml) by a radioimmunoassay kit (Pharmacia
Diagnostics AB, Uppsala, Sweden). A skilled observer who
was unaware of the clinical characteristics of the patients
made cell counts and measurements of ECP concentration
in sputum. If sputum induction was not performed at the
end of the run-in period or the treatment period, the
patient was withdrawn from the study.Drugs and laboratory analysis
Patients were prescribed theophylline sustained-release
tablets (each tablet contained 100 mg anhydrous
theophylline, Guangzhou Maite Xinhua Pharmaceutical
Factory, Guangzhou, China) or matched placebo. The
salmeterol/fluticasone propionate combination product
was purchased from Glaxo Wellcome (Chongqing, China).
The inhalers used were identical in the two treatment
groups.





No. of patients 135 130
Males/females (%) 59.3/40.7 53.8/46.2
Age (yr)
Mean  SDa 45.3  12.4 46.1  14.3
Range 18e65 18e68
Screening pulmonary functiona
FEV1/FVC ratio 53.3  12.7 52.9  13.3
FEV1 (% of Predicted) 56.7  11.3 55.8  12.5
Reversibility in
FEV1 (%)
21.3  6.4 22.6  7.1
FEF25e75% 38.3  17.9 39.2  18.6
350 H. Nie et al.The serum concentration of theophylline was detected
using an automated chemiluminescence system (ACS 180,
USA), with a range of sensitivity of 0.3e40 mg/L.
Statistical analysis
All continuous data are expressed as mean  standard
deviation (SD), and discrete data are expressed as
percentages. Data were analyzed within groups by
Student’s paired t-test or between groups by the Man-
neWhitney U test. Frequency comparisons were analyzed
using the x2 test. A p value of less than 0.05 was considered
to indicate a statistically significant difference. All statis-
tical analysis was performed using SPSS14.0 software (Chi-
cago, Illinois, USA).(% of Predicted)
Diurnal PEF
variability (%)
26.4  7.8 27.2  8.4
Baseline pulmonary function (after 4 wk treatment
with SFC)a
FEV1/FVC ratio 64.4  10.7 65.1  11.8
FEV1 (% of Predicted) 68.8  9.7 70.2  8.9
Reversibility in
FEV1 (%)
15.4  5.9 16.3  6.1
FEF25e75%
(% of Predicted)
44.3  15.8 45.1  16.7
Diurnal PEF
variability (%)
21.8  6.7 22.1  7.1
Baseline ACT scorea 16.3  5.1 15.9  4.6
a Data are presented as mean standard deviation (SD); FEV1,
forced expiratory volume in 1 s; FVC, forced vital capacity;
FEF25e75%, forced expiratory flow between 25% and 75% of FVC;
PEF, peak expiratory flow; SFC, salmeterol/fluticasone propio-
nate combination; ACT, Asthma Control Test.Results
A total of four hundred seven patients were screened.
Eighty-two patients withdrew prior to randomization
because they do not meet the inclusion criteria. Three
hundred twenty-five patients were randomized to treat-
ment with either theophylline plus SFC (n Z 162) or SFC
plus placebo (nZ 163). Of the 325 randomized patients, 60
patients withdrew (27 patients from the theophylline plus
SFC group and 33 patients from the SFC plus placebo
group). The reasons for withdrawal are shown in Table 2.
One hundred thirty-five patients in the theophylline plus
SFC group and 130 patients in the placebo plus SFC group
completed the study according to the protocol and had
valid measurements of the primary variables at baseline.
Their demographic characteristics and baseline data from
the end of the run-in period are outlined in Table 3. The
demographic and baseline characteristics of the two groups
were generally similar, with no significant differences at
baseline in pulmonary function or the mean ACT score.
In the theophylline plus SFC group, the median serum
theophylline concentration was 7.8 mg/L (range,
3.6e15.9 mg/L), which was below the reported therapeutic





No. of patients 162 163













Other reasons 2 1
SFC, salmeterol/fluticasone propionate combination.Sputum induction was successful in patients of both
treatment groups who completed the study according to
study protocol.Assessment of asthma control by the ACT
According to the ACT responses, the majority of patients in
both treatment groups had their asthma well or completely
controlled at the end of the 24-week treatment period.
Well-controlled asthma was achieved in 39.3% (53/135) and
39.2% (51/130) of patients in the theophylline plus SFC
group and in the SFC plus placebo group, respectively, at
the end of the treatment period (p Z 0.996). Completely
controlled asthma was achieved in 42.2% (57/135) and
43.1% (56/130) of patients in the SFC plus theophylline
group and in the SFC plus placebo group, respectively, at
the end of the treatment period (pZ 0.888). We also found
that 18.5% (25/135) and 17.7% (23/130) of patients had
asthma that was insufficiently controlled in the SFC plus
theophylline group and in the SFC plus placebo group,
respectively, at the conclusion of the treatment period
(p Z 0.861). The two treatment groups had no patients
with uncontrolled asthma. The full results are outlined in
Table 4.












0 25 53 57
SFC plus placebo
group
0 23 51 56
p value e 0.861 0.996 0.888
SFC, salmeterol/fluticasone propionate combination.
Theophylline combination therapy on asthma 351There was not a statistically significant difference in the
mean ACT score at baseline between the theophylline plus
SFC group and the SFC plus placebo group (16.3  5.1 and
15.9  4.6, respectively; p > 0.05). Both treatments
resulted in an improvement of the mean ACT score at the
end of the treatment period. In the theophylline plus SFC
group, the mean ACT score increased from 16.3  5.1 at
baseline to 23.6  4.2 at the conclusion of the treatment
period (p < 0.001). In the SFC plus placebo group, the mean
ACT score increased from 15.9  4.6 at baseline to a final
value of 22.9  4.3 (p < 0.001).
The two treatment groups showed similar improvements
in the mean ACT score (p > 0.05). These results are shown
in Fig. 1.
Asthma exacerbations
Eight of the 162 patients randomized to the theophylline
plus SFC group withdrew because of moderate asthma
exacerbations, whereas 12 of the 163 patients randomized
to the placebo plus SFC group withdrew for this reason; this
difference did not reach statistical significance
(p Z 0.363). Further, 2 of 162 patients in the theophylline
plus SFC group withdrew because of severe exacerbationsFigure 1 Mean and SD of ACT scores at baseline and the end
of 24-week treatment period in the theophylline plus SFC group
and the SFC plus placebo group. p < 0.001 compared with
baseline; p > 0.05 compared with the SFC plus placebo group.of asthma, whereas 11 patients randomized to the placebo
plus SFC group withdrew for this reason, and this difference
reached statistical significance (p Z 0.011).
The total number of patients who had at least one
asthma exacerbation was significantly lower in the SFC plus
theophylline group than in the SFC plus placebo group (40
of 135 patients versus 61 of 130 patients, respectively;
p Z 0.004) during the 24-week treatment period. The SFC
plus theophylline group had significantly fewer asthma
exacerbations compared with the SFC plus placebo group
(79 and 152 total exacerbations, respectively; p Z 0.023;
Fig. 2) during the 24-week treatment period.Diurnal PEF variability and spirometry
The spirometry and diurnal PEF variability values observed
for the two treatment groups are outlined in Table 5.
Baseline FEV1, FEV1/FVC ratio and FEF25e75% values were
not significantly different between the two treatment
groups (p > 0.05).
Both treatment regimens resulted in improvements in
pulmonary function at the end of the 24-week treatment
period. In the theophylline plus SFC group, following
observations were noted: the FEV1 values increased from
68.8  9.7% at baseline to a final value of 82.4  10.2% atFigure 2 Cumulative asthma exacerbations in the theoph-
ylline plus SFC group and the SFC plus placebo group.
Table 5 Pulmonary function in the two treatment groups





FEV1 (% of Predicted)
Baseline 68.8  9.7 70.2  8.9
End of treatment 82.4  10.2a 81.3  8.7a
FEV1/FVC ratio (%)
Baseline 64.4  10.7 65.1  11.8
End of treatment 80.9  8.7a 81.2  9.1a
FEF25e75% (% of Predicted)
Baseline 44.3  15.6 45.1  16.7
End of treatment 66.9  18.8a,b 57.4  17.6a
Diurnal PEF variability (%)
Baseline 21.8  6.7 22.1  7.1
End of treatment 10.9  3.2a 11.5  3.4a
Data are presented as mean  standard deviation (SD); FEV1,
forced expiratory volume in 1 s; FVC, forced vital capacity;
FEF25e75%, forced expiratory flow between 25% and 75% of FVC;
PEF, peak expiratory flow; SFC, salmeterol/fluticasone propio-
nate combination.
a p < 0.001 compared with baseline.
b p < 0.001 compared with SFC plus placebo group.
Table 6 Inflammatory markers detected in the induced
sputum of the two treatment groups at baseline and at the






Baseline 13.1  6.2 12.7  5.8
End of treatment 4.1  2.2a,b 6.3  2.7a
Macrophage (%)
Baseline 47.6  11.8 48.1  12.1
End of treatment 61.8  10.7 58.9  12.9
Neutrophil (%)
Baseline 30.7  11.8 31.9  12.7
End of treatment 25.1  9.2 26.8  11.1
Lymphocyte (%)
Baseline 3.8  1.7 4.2  1.9
End of treatment 3.5  1.8 4.3  2.4
ECP (mg/L)
Baseline 176.4  89.4 171.7  93.4
End of treatment 63.6  39.5a,b 89.4  45.6a
Data are presented as mean  standard deviation (SD); ECP,
eosinophil cationic protein; SFC, salmeterol/fluticasone propi-
onate combination.
a p < 0.001 compared with baseline.
b p < 0.01 compared with SFC plus placebo group.
352 H. Nie et al.the conclusion of the treatment period (p < 0.001); the
FEV1/FVC ratio increased from 64.4  10.7% at baseline to
a final value of 80.9  8.7% (p < 0.001); FEF25e75% increased
from a baseline value of 44.3  15.8% to 66.9  18.8% at the
end of the treatment period (p < 0.001); and diurnal FEF
variability decreased from 21.8  6.7% at baseline to
10.9  3.2% at the end of the treatment period (p < 0.001).
In the SFC plus placebo group, the following improvements
were recorded: the FEV1 values increased from 70.2  8.9%
at baseline to a final value of 81.3  8.7% (p < 0.001); the
FEV1/FVC ratio rose from 65.1  11.8% at baseline to a final
value of 81.2  9.1% (p < 0.001); FEF25e75% increased from
a baseline value of 45.1  16.7% to 57.4  17.6% at the end
of the treatment period (p < 0.001); diurnal PEF variability
decreased from 22.1  7.1% at baseline to 11.5  3.4% at
the end of the treatment period (p < 0.001).
Analyses of overall treatment effects of two treatments
showed similar improvements in FEV1, FEV1/FVC ratio and
diurnal PEF variability (all p > 0.05). SFC plus theophylline
was superior to SFC plus placebo in terms of FEF25e75%
values (p < 0.001).
Inflammatory markers in induced sputum
The results of assays for inflammatory markers in the
induced sputum of patients are outlined in Table 6. The
eosinophil counts and ECP concentrations were not signifi-
cantly different between the two treatment groups at
baseline (all p > 0.05).
Both treatments resulted in an improvement in the
levels of inflammatory markers in induced sputum at the
end of 24-week treatment period. In the theophylline plus
SFC group, a comparison of the baseline observations to
those made at the end of 24-week treatment revealed that
there were reductions in both the eosinophil count
(13.1  6.2% to 4.1  2.2%) and concentration of ECP(176.4  89.4 to 63.6  39.5 mg/L) in induced sputum (all
p < 0.001). In the SFC plus placebo group, there were also
reductions in eosinophil count (12.7  5.8% to 6.3  2.7%)
and ECP concentration (171.7  93.4 to 89.4  45.6 mg/L) in
induced sputum when comparing baseline observations to
those made at the end of 24-week treatment period (all
p < 0.001).
Our analyses of the overall impact of both treatment
combinations revealed greater improvements in eosinophil
counts and ECP concentrations in the induced sputum of
patients belonging to the SFC plus theophylline group than
in those of the SFC plus placebo group (all p < 0.01).
Discussion
The results of our present study clearly demonstrated that
both treatments resulted in improvement in the control of
asthma, as assessed by the ACT, pulmonary function and
inflammatory markers in induced sputum. Both SFC plus
theophylline and SFC alone produced similar results with
regards to asthma control and pulmonary function, as seen
by the changes in the FEV1, FEV1/FVC ratio and diurnal FEF
variability. However, our study also showed that there was
a significant reduction in the number of patients with at
least one exacerbation, as well as the cumulative number
of asthma exacerbations, when comparing the SFC plus
theophylline group to the SFC plus placebo group.
Furthermore, improvements in FEF25e75% and control of
eosinophilic airway inflammation were greater in the SFC
plus theophylline group than in the SFC plus placebo group.
In the majority of patients, asthma can be reasonably
well controlled with simple regimens of inhaled drugs.
However, some patients suffer from frequent asthma
exacerbations, which results in days of absence from work
Theophylline combination therapy on asthma 353or school, the need for emergency treatment or admission
to hospital. Such exacerbations are associated with
morbidity and account for a substantial proportion of the
total economic costs of this disease.15 Therefore, preven-
tion of asthma exacerbations is an important goal in the
management of asthma. At the end of 24-week treatment
period of our study, the asthma of the majority of patients
was well or completely controlled in the two treatment
groups according to the ACT. However, the number of
patients who had at least one asthma exacerbation, and
cumulative number of asthma exacerbations, were signifi-
cantly lower in the SFC plus theophylline group than in the
SFC plus placebo group. Accordingly, for preventing asthma
exacerbations, our data suggests that the combination of
SFC plus theophylline may be superior to administration of
SFC alone.
Asthma is characterized by chronic airway inflammation
and associated airway hyperresponsiveness. Inflammation
in asthma involves both large and small airways.16 Evidence
suggests that inflammation in small airways, which are
<2 mm in diameter, contributes significantly to the path-
ogenesis of asthma.17 Small airway involvement in asthma
is prominent in severe persistent asthma,18 and has also
been demonstrated to play a role in mild to moderate
asthma.19 Early closure of small airways, perhaps due to
uncontrolled inflammation, has been shown to characterize
patients with “difficult to control asthma”.20 Thus, small
airways may be an important therapeutic target.21 In order
to assess expiratory airflow obstruction in asthma patients,
FEV1 or PEF are generally used as measures of lung func-
tion, as they have been demonstrated to have greater
reproducibility than other measures; however, they pref-
erentially reflect changes in the large airways. Due to the
difficulty of in vivo sampling and a lack of pulmonary
function tests specific to this site, small airway obstruction
in patients with asthma has been largely under-evaluated.
The forced expiratory flow between 25% and 75% of
forced vital capacity (FEF25e75%) is the spirometric variable
most commonly cited as an indicator of small airway
obstruction.22 In our study, the two treatment combina-
tions employed showed similar improvements in FEV1,
FEV1/FVC ratio and diurnal FEF variability; however, the
SFC plus theophylline group was superior to SFC alone in
terms of FEF25e75% measurements. Our data thus indicates
that the addition of theophylline to SFC provided a greater
benefit than SFC alone on the function of small airways in
patients with asthma.
Ideally, assessment of asthma severity and effectiveness
of treatment should be guided directly by the degree of
airway inflammation.1 At present, sputum induction has
been proposed as a relatively less invasive method for
assessing airway secretion, and provided markers of airway
inflammation are in agreement with those from bron-
choalveolar lavage and biopsy specimens in asthmatic
patients.23 Sputum induction has evolved to a point where
it is repeatable, valid and responsive, and it appears to
provide meaningful information about inflammatory events
in the lower airways. The use of sputum to investigate
airway inflammation also has the great advantage of being
non-invasive and thus safe, feasible and suitable for
repeated measurement in most patients.24 In our study,
eosinophil count and ECP concentration were similar inboth treatment groups at baseline, though greater
improvements in eosinophil count and concentration of ECP
in induced sputum were observed in the SFC plus theoph-
ylline group than in the SFC plus placebo group. Our data
suggests that the combination of theophylline plus SFC may
have a greater effect on airway inflammation in patients
with asthma. Although ICS anti-inflammatory treatment,
with or without long-acting b2 agonists (LABAs), is the
cornerstone of asthma management, the most commonly
used formulations are deposited in relatively low amounts
in the peripheral airways, a reflection of their unfavorable
aerodynamic properties.25 Anti-inflammatory treatment
needs to be directed to both large and distal airways if
maximal suppression of airway inflammation is to be ach-
ieved.26 We therefore postulate that the greater improve-
ment in airway inflammation in the SFC plus theophylline
group than in the SFC plus placebo group may be attrib-
uted, at least in part, to poor delivery of inhaled medica-
tions to small airways, leading to insufficient control of
inflammation; oral theophylline, on the other hand, would
appear to have access to this area of the lung through the
circulation. However, specific studies are necessary to
confirm the potential action of theophylline on small airway
inflammation.
Theophylline is used worldwide for the treatment of
asthma. It is a bronchodilator that also has extrapulmonary
effects, including anti-inflammatory effects.8,9 The bron-
chodilator effect of theophylline may be related to phos-
phodiesterase inhibition, which is observed at high serum
concentrations (10e20 mg/mL), while the anti-inflammatory
effect is observed at lower serum concentrations (5e10 mg/
mL theophylline).27 In our study, the median serum theoph-
ylline concentrationwas 7.8 mg/mL (range, 3.6e15.9 mg/mL)
in the theophylline plus SFC group. Therefore, we propose
that the superior treatment outcomes seenwith the addition
of theophylline with regards to the number of asthma
exacerbations and FEF25e75% may be related to its anti-
inflammatory properties.
In summary, our results show that the addition of
theophylline is beneficial in asthma patients who are also
being treated with inhaled corticosteroids and long-acting
b2 agonists. The observed effects were achieved at low
dose of theophylline, thus minimizing adverse side
effects.10 Improved protection against asthma exacerba-
tions due to improvements in small airway function
parameters and reduced airway inflammation may be ach-
ieved with theophylline in combination with SFC.
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